ACE2 variant (prolonged half-life)

Angiotensin Therapeutics is developing an engineered, recombinant fusion protein variant of angiotensin-converting enzyme 2 (ACE2) for the treatment of kidney diseases, including acute kidney injury (AKI), chronic kidney disease (CKD), and diabetic kidney disease (DKD). Unlike native ACE2, which has a molecular weight of approximately 100-110 kDa, this engineered variant is smaller (around 70 kDa), a design intended to facilitate glomerular filtration and subsequent tubular uptake. The protein is modified with half-life extending tags, such as Fc fusion, to prolong its enzymatic activity from a few hours to more than three days. Its primary mechanism of action involves the conversion of angiotensin II into angiotensin-(1-7), thereby mitigating the overactivity of the renin-angiotensin system (RAS) within the kidney. Additionally, the molecule may function as a soluble decoy receptor. The program is currently in the preclinical stage of development.

Other names

recombinant fusion ACE2engineered ACE2 variantACE2 variant with prolonged half-lifeACE-2 variant with prolonged half-lifeACE 2 variant with prolonged half-life